Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 6/20 | 0.31 |
| ▸ | JAK1 | P23458 | 6/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876437 | 0.91 | F10 (0.33) | F10PDK2JAK2JAK1 | |
| SCHEMBL876499 | 0.86 | SLC2A1 (0.35) | F10PDK2JAK2JAK1 | |
| SCHEMBL875680 | 0.85 | F10 (0.33) | F10PDK2JAK2JAK1 | |
| SCHEMBL877626 | 0.82 | TLR9 (0.37) | TLR9TLR8TLR7F10PDK2 | |
| SCHEMBL878362 | 0.79 | TLR9 (0.36) | TLR9TLR8TLR7F10JAK2 | |
| SCHEMBL876160 | 0.79 | F10 (0.33) | F10 | |
| SCHEMBL878326 | 0.77 | TLR9 (0.39) | TLR9TLR8TLR7F10PDK2 | |
| SCHEMBL876778 | 0.75 | BDKRB1 (0.39) | F10 | |
| SCHEMBL876715 | 0.74 | CCR5 (0.37) | F10PDK2JAK2JAK1ADORA2A | |
| SCHEMBL785591 | 0.74 | F10 (0.44) | TLR9TLR8TLR7F10PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |